Compare Recursion Pharmaceuticals Inc (RXRX) vs Direxion Daily TSLA Bull 2X Shares (TSLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Direxion Daily TSLA Bull 2X Shares — how do they compare? Recursion Pharmaceuticals Inc trades at $4.01 (market cap $2.31B), while Direxion Daily TSLA Bull 2X Shares trades at $10.23 (market cap $4.08B). The key difference: Direxion Daily TSLA Bull 2X Shares is the larger of the two by market cap, and Direxion Daily TSLA Bull 2X Shares is more actively traded (46,206,477 versus 40,478,768). Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Direxion Daily TSLA Bull 2X Shares for 15 Days on average.
| RXRX | TSLL | |
|---|---|---|
Market Cap | $2.31B | $4.08B |
Volume | 40,478,768 | 46,206,477 |
Sector | Health | Leveraged / Inverse |
52-Week High | $6.79 | $23.03 |
52-Week Low | $2.84 | $6.74 |
Typical Hold Time | 22 Days | 15 Days |
Enterprise Value | $1.83B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
TSLL, the Direxion Daily TSLA Bull 2X Shares ETF, trades at $10.15, down 1.55% on the day. The overall technical signal is bullish, supported by moving averages, while oscillators are neutral. Recent news highlights its sensitivity to Tesla's stock movements, with a notable rally tied to Cybercab hype. As a leveraged ETF, it aims to deliver twice Tesla's daily returns, amplifying both gains and losses.
The outlook for TSLL is directly tied to Tesla's performance, offering high-risk, high-reward exposure. Key risks include volatility decay from daily rebalancing and dependence on Tesla-specific events. Investors seeking amplified Tesla returns may find opportunity, but must be wary of the inherent leverage risks in a volatile stock.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →
